Abstract 58P
Background
Vepdegestrant (ARV-471) is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. Based on results of the phase 2 cohort expansion (VERITAC) of a phase 1/2 study (NCT04072952), vepdegestrant 200 mg once daily (QD) was selected as the recommended phase 3 dose (RP3D). This phase 1 study (NCT05463952) investigated the safety, PK, and preliminary efficacy of vepdegestrant in Japanese patients with ER+/HER2- advanced breast cancer at the RP3D.
Methods
Patients with ER+/HER2- advanced breast cancer who were resistant to standard therapy or for whom no standard therapy was available or who had received ≥2 prior endocrine therapies in any setting were eligible. Vepdegestrant 200 mg was given QD with food. The primary endpoint was dose-limiting toxicities (DLTs) in cycle 1; secondary endpoints included safety, PK, and antitumor activity.
Results
Six female patients were treated; median age was 58 years (range: 47–62). Five patients received ≥3 prior regimens for advanced disease; 5 patients received prior CDK4/6 inhibitors. At the data cutoff (May 4, 2023), median treatment duration was 9.8 weeks (range: 6–28); 2 patients remained on treatment. No DLTs were observed. Four (66.7%) patients experienced adverse events (AEs); none led to dose reduction or discontinuation. Treatment-related AEs were abdominal discomfort, anemia, dizziness, increased alanine aminotransferase, increased aspartate aminotransferase, nausea, and pruritus (1 event each); all were grade 1 except anemia (grade 2). Geometric mean Cmax and AUC24 of vepdegestrant were 630.9 ng/mL and 10,400 ng•hr/mL after a single dose and 1056 ng/mL and 18,310 ng•hr/mL after multiple doses. Two patients demonstrated stable disease at week 24 assessment.
Conclusions
The RP3D of vepdegestrant 200 mg QD was well tolerated in Japanese patients with ER+/HER2- advanced breast cancer. Vepdegestrant will be evaluated in 2 global, randomized phase 3 studies in patients with ER+/HER2- advanced breast cancer: as second/third-line monotherapy in VERITAC-2 (NCT05654623) and as first-line therapy in combination with palbociclib in VERITAC-3 (NCT05909397).
Clinical trial identification
NCT05463952.
Editorial acknowledgement
Editorial support provided by Nathan Yardley, PhD, and Melissa Austin of Apollo Medical Communications, part of Helios Global Group, and funded by Arvinas Operations, Inc.
Legal entity responsible for the study
Pfizer, Inc.
Funding
Pfizer, Inc.
Disclosure
H. Iwata: Financial Interests, Personal, Advisory Board: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Sanofi; Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Pfizer, Sanofi, Taiho; Financial Interests, Personal and Institutional, Steering Committee Member: Chugai, Daiichi Sankyo, AstraZeneca, MSD, Amgen, Sanofi, Novartis, Pfizer, Kyowa Hakko Kirin; Financial Interests, Personal and Institutional, Local PI: Lilly, Bayer, Behringer, Nihon Kayaku. Y. Naito: Financial Interests, Personal, Invited Speaker, Speakers Bureau: Chugai, Pfizer, Eli Lilly, Eisai, AstraZeneca, PDR pharma, Novartis, Gardant, Ono, Takeda, Taiho, Bayer, Nihon Kayaku, Daiichi Sankyo, Bristol, MSD; Financial Interests, Personal, Funding: Roche; Financial Interests, Personal, Local PI: AbbVie, Boehringer Ingelheim, Ono, Chugai, Taiho, Pfizer, AstraZeneca, Gilead, Takeda; Financial Interests, Personal, Steering Committee Member: Daiichi Sankyo; Non-Financial Interests, Personal, Principal Investigator, JCOG: Natera. M. Hattori: Financial Interests, Personal, Speaker’s Bureau: Pfizer. K. Yonemori: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, Sanofi, Genmab, Gliad, OncoXerna, Takeda, Novartis, MSD; Financial Interests, Personal, Invited Speaker: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Ono, BMS, Boeringer Ingerheim, Daiichi Sankyo, Bayer, Jansen, Sanofi; Financial Interests, Institutional, Local PI: MSD, Daiichi Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seagen, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirrin, Nihon Kayaku, Haihe. M. Aizawa, J. Yoshimitsu: Financial Interests, Personal, Full or part-time Employment: Pfizer R&D Japan. Y. Mori, Y. Umeyama: Financial Interests, Personal, Full or part-time Employment: Pfizer R&D Japan; Financial Interests, Personal, Stocks/Shares: Pfizer Inc. T. Mukohara: Financial Interests, Personal, Research Grant: Daiichi Sankyo, Sysmex, Eisai, MSD, Pfizer, Novartis, Sanofi, Chugai, AstraZeneca, Ono; Financial Interests, Personal, Speaker, Consultant, Advisor, Lecture fees: Eisai, Pfizer, Novartis, Chugai, Eli Lilly, AstraZeneca, Kyowa-Kirin, Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract